Anti-CD20 Monoclonal Antibodies (mABs) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Oct 2023

Pages: 161

SKU: IRTNTR73017

Snapshot

Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028

The anti-cd20 monoclonal antibodies (mABs) market size is estimated to grow by USD 11.43 billion accelerating at a CAGR of 10.31% between 2023 and 2028.

Key Findings:

Anti-cd20 monoclonal antibodies (mABs) market remained historically at high levels from 2018 to 2023.
The market is segmented into Product, Type, and Geography.
Oncology sub segment under the product segment cateogory generated the largest revenue in 2018.
Key regions boosting the market growth include North America, Europe, Asia, and Rest of World (ROW).

Anti-cd20 monoclonal antibodies (mABs) market Share

For More Highlights About this Report, Download Free Sample in a Minute

Anti-CD20 Monoclonal Antibodies (mABs) Market: Key Drivers, Trends and Challenges

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Anti-CD20 Monoclonal Antibodies (mABs) Market Driver

Increased use of combination therapies is the key factor driving market growth. Combination therapy is often preferred when monotherapy products are less effective and poorly tolerated. The market has witnessed a significant increase in the use of anti-CD20 mABs in combination with other drugs to target comorbidity diseases. Usually, combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, the use of drugs in combination increases the tolerability, as two compounds can be employed below their individual dose thresholds.

Furthermore, the market has witnessed multiple approvals for anti-CD20 mABs as combination therapy for the treatment of various indications in recent years. Hence, the higher efficacy of anti-CD20 mABs when used in combination therapy than monotherapy is anticipated to boost the adoption rate of therapeutics, which will drive the growth of the market during the forecast period.

Key Anti-CD20 Monoclonal Antibodies (mABs) Market Trends

The development of CD20 bispecific antibodies is the primary trend shaping market growth. Bispecific antibodies are combinations of two or more antigens in one product and are capable of binding to two or more specific targets, through multiple pathways in the target disease. Simultaneous blocking of multiple biological pathways allows bispecific antibodies to exhibit synergistic effects, which is not possible with mixtures of monospecific antibodies.

Moreover, the use of bispecific antibodies makes it possible to optimize expenses by reducing the cost of drug development and clinical trials. Furthermore, due to the dual and synergistic mechanism of these bispecific antibodies, several companies are developing bispecific CD20/CD3 mABs to treat several CD20-positive diseases. Hence, the development of CD20 bispecific antibodies is one of the trends that is anticipated to drive the growth of the market during the forecast period.

Major Anti-CD20 Monoclonal Antibodies (mABs) Market Challenge

Adverse effects of anti-CD20 mABs is a challenge that affects market growth. Although anti-CD20 mABs are widely used to treat CD20-positive conditions, due to their high target affinity and safety profile, serious negative effects associated with their use pose a threat to the development of the global anti-CD20 monoclonal antibodies (mABs) market.

Moreover, some of the serious side effects of anti-CD20 mABs included with Rituximab are chest pain, irregular heartbeats, and kidney problems. With Obinutuzumab are hepatitis B virus reactivation, and hyponatremia. Ocrelizumab increases the risk of respiratory tract infections. Due to serious side effects associated with anti-CD20 mABs, patients prefer alternative treatment options, which may impede the growth of the market during the forecast period.

Anti-CD20 Monoclonal Antibodies (mABs) Market Segmentations

The product segment includes oncology, neurology, and immunology. The type segment includes first generation anti-CD20 monoclonal antibody, second generation anti-CD20 monoclonal antibody, and third generation anti-CD20 monoclonal antibody. The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW).

Product Segment

The market share growth by the oncology segment will be significant during the forecast period. The growth of the oncology segment is largely due to the availability of anti-CD20 mAb to treat common cancer indications. The high incidence and prevalence of cancer is expected to drive the growth of this segment.

Get a glance at the market contribution of various segments Download the PDF Sample

The oncology segment was valued at USD 6.73 billion in 2018. However, the growth of this segment is expected to decrease with the introduction of rituximab biosimilars, especially in Europe. The introduction of low-cost biosimilars will hinder the sales of branded drugs, which are highly priced, which, in turn, will limit the growth of the segment in the anti-cd20 monoclonal antibodies market during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 57% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The growth of the anti-CD20 monoclonal antibody (mAB) market in North America is due to the high incidence and prevalence of hematological malignancies such as non-Hodgkin lymphoma (NHL).

In addition, the growth of the market in the region is driven by recent approvals for anti-CD20 mABs in the region. Additionally, the anti-cd20 monoclonal antibodies market growth in this region is expected to be driven by the continuous demand for OCREVUS, owing to the increasing incidence and relapsed cases of multiple sclerosis. Furthermore, the expected approval of late-stage pipeline drugs is also estimated to propel the market growth in this region during the forecast period.

Key Companies in Anti-CD20 Monoclonal Antibodies (mABs) Market

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Amgen Inc.: The company offers anti CD20 monoclonal antibodies such as Bax active monomer recombinant antibody 6A7 OAAV00544 and CD52 recombinant antibody campath 1H OAAV00552.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Anti-CD20 Monoclonal Antibodies (mABs) Market Scope
Report Coverage	Details
Page number	161
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 10.31%
Market growth 2024-2028	USD 11.43 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	9.85
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 57%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in this Anti-CD20 Monoclonal Antibodies (mABs) Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2024 and 2028
Precise estimation of the size of the market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behaviour
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global anti-CD20 monoclonal antibodies (mABs) market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global anti-cd20 monoclonal antibodies (mabs) market 2018 - 2022 ($ billion)

4.2 Product Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Product Segment 2018 - 2022 ($ billion)

4.3 Type Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

6.1 Market segments
- Exhibit 30: Chart on Product - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Product - Market share 2023-2028 (%)

6.2 Comparison by Product
- Exhibit 32: Chart on Comparison by Product
- Exhibit 33: Data Table on Comparison by Product

6.3 Oncology - Market size and forecast 2023-2028
- Exhibit 34: Chart on Oncology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)

6.4 Neurology - Market size and forecast 2023-2028
- Exhibit 38: Chart on Neurology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Neurology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Neurology - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Neurology - Year-over-year growth 2023-2028 (%)

6.5 Immunology - Market size and forecast 2023-2028
- Exhibit 42: Chart on Immunology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Immunology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Immunology - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Immunology - Year-over-year growth 2023-2028 (%)

6.6 Market opportunity by Product
- Exhibit 46: Market opportunity by Product ($ billion)
- Exhibit 47: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Type

7.1 Market segments
- Exhibit 48: Chart on Type - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Type - Market share 2023-2028 (%)

7.2 Comparison by Type
- Exhibit 50: Chart on Comparison by Type
- Exhibit 51: Data Table on Comparison by Type

7.3 First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
- Exhibit 52: Chart on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)

7.4 Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
- Exhibit 56: Chart on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)

7.5 Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
- Exhibit 60: Chart on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ billion)
- Exhibit 61: Data Table on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ billion)
- Exhibit 62: Chart on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Type
- Exhibit 64: Market opportunity by Type ($ billion)
- Exhibit 65: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2023-2028 (%)
- Exhibit 68: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Canada - Market size and forecast 2023-2028
- Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 China - Market size and forecast 2023-2028
- Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ billion)
- Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 Acrotech Biopharma Inc.
- Exhibit 115: Acrotech Biopharma Inc. - Overview
- Exhibit 116: Acrotech Biopharma Inc. - Product / Service
- Exhibit 117: Acrotech Biopharma Inc. - Key offerings

12.4 Amgen Inc.
- Exhibit 118: Amgen Inc. - Overview
- Exhibit 119: Amgen Inc. - Product / Service
- Exhibit 120: Amgen Inc. - Key offerings

12.5 AstraZeneca Plc
- Exhibit 121: AstraZeneca Plc - Overview
- Exhibit 122: AstraZeneca Plc - Product / Service
- Exhibit 123: AstraZeneca Plc - Key news
- Exhibit 124: AstraZeneca Plc - Key offerings

12.6 Celltrion Healthcare Co. Ltd.
- Exhibit 125: Celltrion Healthcare Co. Ltd. - Overview
- Exhibit 126: Celltrion Healthcare Co. Ltd. - Product / Service
- Exhibit 127: Celltrion Healthcare Co. Ltd. - Key offerings

12.7 F. Hoffmann La Roche Ltd.
- Exhibit 128: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 129: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 130: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 131: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 132: F. Hoffmann La Roche Ltd. - Segment focus

12.8 Fosun International Ltd.
- Exhibit 133: Fosun International Ltd. - Overview
- Exhibit 134: Fosun International Ltd. - Product / Service
- Exhibit 135: Fosun International Ltd. - Key offerings

12.9 Genmab AS
- Exhibit 136: Genmab AS - Overview
- Exhibit 137: Genmab AS - Key offerings

12.10 IGM Biosciences Inc.
- Exhibit 138: IGM Biosciences Inc. - Overview
- Exhibit 139: IGM Biosciences Inc. - Product / Service
- Exhibit 140: IGM Biosciences Inc. - Key offerings

12.11 JSC BIOCAD
- Exhibit 141: JSC BIOCAD - Overview
- Exhibit 142: JSC BIOCAD - Product / Service
- Exhibit 143: JSC BIOCAD - Key offerings

12.12 LFB SA
- Exhibit 144: LFB SA - Overview
- Exhibit 145: LFB SA - Product / Service
- Exhibit 146: LFB SA - Key offerings

12.13 Novartis AG
- Exhibit 147: Novartis AG - Overview
- Exhibit 148: Novartis AG - Business segments
- Exhibit 149: Novartis AG - Key offerings
- Exhibit 150: Novartis AG - Segment focus

12.14 Pfizer Inc.
- Exhibit 151: Pfizer Inc. - Overview
- Exhibit 152: Pfizer Inc. - Product / Service
- Exhibit 153: Pfizer Inc. - Key news
- Exhibit 154: Pfizer Inc. - Key offerings

12.15 Regeneron Pharmaceuticals Inc.
- Exhibit 155: Regeneron Pharmaceuticals Inc. - Overview
- Exhibit 156: Regeneron Pharmaceuticals Inc. - Product / Service
- Exhibit 157: Regeneron Pharmaceuticals Inc. - Key offerings

12.16 Spectrum Pharmaceuticals Inc.
- Exhibit 158: Spectrum Pharmaceuticals Inc. - Overview
- Exhibit 159: Spectrum Pharmaceuticals Inc. - Product / Service
- Exhibit 160: Spectrum Pharmaceuticals Inc. - Key offerings

12.17 TG Therapeutics Inc.
- Exhibit 161: TG Therapeutics Inc. - Overview
- Exhibit 162: TG Therapeutics Inc. - Product / Service
- Exhibit 163: TG Therapeutics Inc. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 164: Inclusions checklist
- Exhibit 165: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 166: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 167: Research methodology
- Exhibit 168: Validation techniques employed for market sizing
- Exhibit 169: Information sources

13.5 List of abbreviations
- Exhibit 170: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

anti-cd20 monoclonal antibodies (mabs) market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis